Physician profile
Natalie Johnson
NPI 1679868517
$778.99
in general payments reported to CMS, 2019-2025
21 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $66.61 · 2021: $29.32 · 2022: $78.56 · 2023: $38.13 · 2024: $173 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126.34 | 2020-2025 | |
| Amgen INC. | $77.26 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $70.89 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $64.85 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Lilly USA, LLC | $54.84 | 2025 | Zepbound, Mounjaro |
| Sage Therapeutics, LLC | $54.14 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $44.68 | 2024 | Veozah |
| Organon LLC | $43.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.31 | 2019 | |
| Mylan Specialty L.P. | $25.31 | 2024 | Yupelri |
| Genzyme Corporation | $24.13 | 2023 | |
| Allergan, INC. | $22.82 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.15 | 2025 | Qelbree |
| Tactile Systems Technology INC | $19.18 | 2024 | Flexitouch Plus, Entre Plus |
| Viatris Specialty LLC | $17.85 | 2025 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $15.96 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.02 | 2020 | |
| Dexcom, INC. | $14.00 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $13.75 | 2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Novo Nordisk INC | $12.52 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.